Biohaven (BHVN) Total Debt (2025 - 2026)

Biohaven (BHVN) posted Total Debt of $241.9 million for Q1 2026, up 1.26% sequentially from $238.9 million in Q4 2025.

Biohaven (BHVN) Total Debt (2025 - 2026) Analysis & Trends

Biohaven has reported Total Debt for 2 years, with the latest figure at $241.9 million in Q1 2026.

Quarterly Total Debt changed N/A year-over-year to $241.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $241.9 million (changed N/A YoY) and the FY2025 annual result came in at $238.9 million, changed N/A from the prior year.
Total Debt grew to $241.9 million in Q1 2026 per BHVN's latest filing, from $238.9 million in the prior quarter.
Over five years, Total Debt peaked at $268.3 million in Q3 2025 and troughed at $238.9 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Biohaven	2.21 Bn	1.94 Bn	-	259.48 Mn

Download Data